Research ArticleCancer

CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors

See allHide authors and affiliations

Science Translational Medicine  11 Jul 2018:
Vol. 10, Issue 449, eaao3240
DOI: 10.1126/scitranslmed.aao3240

Article Information

vol. 10 no. 449

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication July 7, 2017
  • Resubmitted November 30, 2017
  • Accepted for publication May 17, 2018

Author Information

  1. Clemens Reinshagen1,2,3,
  2. Deepak Bhere1,2,3,
  3. Sung Hugh Choi1,2,3,
  4. Stefan Hutten3,
  5. Irina Nesterenko3,
  6. Hiroaki Wakimoto1,2,4,
  7. Eloi Le Roux3,
  8. Alia Rizvi3,
  9. Wanlu Du3,
  10. Charles Minicucci3 and
  11. Khalid Shah1,2,3,5,*
  1. 1Center for Stem Cell Therapeutics and Imaging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.
  2. 2Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA.
  3. 3Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  4. 4Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
  5. 5Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.
  1. *Corresponding author. Email: kshah{at}bwh.harvard.edu

Altmetric

Article usage

Article usage: July 2018 to September 2018

AbstractFullPdf
Jul 20182340216082223
Aug 20188066865484
Sep 20182959338190